- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03225625
Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study (SciExVR)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality (SciExVR) study is based on the progress that researchers have made treating spinal cord injury (SCI) with bone marrow derived stem cells (BMSC). While major improvements have remained elusive with other approaches, modest benefits have been achieved.
The use of subarachnoid BMSC provided via intrathecal injection has resulted in improvements for certain sensory and bladder functions. Exoskeleton treatment has shown certain benefits in sensory, bowel and bladder function.
Intravenous (IV) BMSC have benefited stroke and other central nervous system damage. In the sponsor's concomitant Neurologic Stem Cell Treatment (NEST) study for general neurologic disease, benefit has been shown by combining IV with intranasal BMSC.
The SciExVR study uses paraspinal injections- meaning the BMSC are placed adjacent to the spinal nerves which enter the spinal canal through the intervertebral foramen of the vertebral bodies. The BMSC will be placed at the level of the injury on both sides of the spine as well as approximately two segments above and two segments below. The investigators believe this will allow entry into the spinal tissue at the injury site as well as to the injured upper motor neuron pathways; lower motor neurons which may be injured; sensory pathways; dorsal root ganglia at and below the site and autonomic ganglia. Placement in the paraspinal tissue may extend the time that BMSC have to proliferate at, above and below the vicinity of the spinal cord injury and interact with damaged cells in the spinal cord, spinal roots, spinal nerves and paravertebral ganglion. Potential benefits of these interactions include BMSC mitochondrial transfer to target cells, secretion of mRNA increasing target cell activity, secretion of nerve growth factor and other neurotrophic factors beneficial to nerve regrowth. Increased proliferation and contact time may increase neuronal transdifferentiation of BMSC to neurons and/or neuroglia. Following paraspinal injections the patient receives the remaining BMSC intravenously (IV) and also topically intranasally. BMSC given IV may enter the central nervous system through the paraventricular organs in the brain to potentially reach the ascending and descending pathways, thalamus, sensory cortex, motor cortex and circulate through the cerebral spinal fluid (CSF). Intranasal provides access through the axons of the Trigeminal (V) cranial nerves and entry into the brain at the level of the pons with similar opportunity to move through the tissues.
BMSC are separated from bone marrow obtained from the posterior iliac crest with a single aspiration on each side. The procedure is performed under general or MAC anesthesia at the fully licensed surgical center so there is no discomfort in performing the procedure. The BMSC are separated from the aspirate using an FDA cleared class II device.
After BMSC treatment patients who are in Arm 1 simply follow up with their own neurologists at 1,3,6 and 12 months.
Those in Arm 2 require similar follow up and pursue treatment at centers that can provide exoskeletal stimulation or physical therapy equivalent. Exoskeleton devices move the limbs of the patient to provide stimulation to the muscles in a self directed fashion but similar to physical therapy that is often performed for SCI. The investigators believe that Arm 2 may provide stimulation of the upper and lower motor neurons and sensory receptors such as exteroceptors and proprioceptors which may, in the presence of BMSC, assist in regeneration or reactivation of the spinal cord pathways.
Patients in Arm 3 require similar follow up and may use Virtual Reality headsets or equivalent to increase visualization of movement of the lower extremities and/or sensory feedback. This may also help stimulate the upper and lower motor neurons and sensory receptors.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Coral Springs, Florida, United States, 33063
- MD Stem Cells
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have documented functional damage to the spinal cord unlikely to improve with present standard of care.
- If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated spinal cord damage as a result of the ongoing pharmacologic or surgical treatment.
- In the estimation of Dr. Weiss and Dr. Silberfarb have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.
- Be over the age of 18 and capable of providing informed consent.
- Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.
Exclusion Criteria:
- All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.
- Patients must be capable and willing to undergo follow up neurologic exams as outlined in the protocol.
- Patients must be capable of providing informed consent.
- In the estimation of Dr. Weiss and Dr. Silberfarb the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .
- Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.
- Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Paraspinal
Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level.
Following paraspinal injection remaining BMSC provided intravenous and intranasal.
|
BMSC provided by paraspinal injection, intravenous and intranasal
Other Names:
|
Experimental: Paraspinal EX
Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal. Exoskeleton or equivalent stimulation following this treatment. |
BMSC provided by paraspinal injection, intravenous and intranasal
Other Names:
BMSC provided by paraspinal injections, intravenous and intranasal followed by exoskeleton or equivalent stimulation
Other Names:
|
Experimental: Paraspinal VR
Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal. Virtual Reality or equivalent visualization following this treatment. |
BMSC provided by paraspinal injection, intravenous and intranasal
Other Names:
BMSC provided by paraspinal injections, intravenous and intranasal followed by virtual reality or equivalent visualization
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
American Spinal Injury Association (ASIA) Impairment Scale (AIS)
Time Frame: Pre-procedure, 1,3,6 and 12 months post-procedure
|
AIS is based on the Frankel scale which is used to classify the degree or completeness of spinal cord injury (SCI) by assessing motor and sensory function.
Patients will have AIS assessment prior to procedure and post-procedure for comparison and identification of any improvements in motor or sensory function.
|
Pre-procedure, 1,3,6 and 12 months post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Autonomic Nervous System (ANS) Function
Time Frame: 1,3,6 and 12 months post-procedure
|
The autonomic nervous system (ANS) through the sympathetic and parasympathetic divisions is responsible for many functions of the body including bladder and bowel control and sweating.
Patients will self-report changes in ANS function and their abilities to perform ANS functions following the procedure.
|
1,3,6 and 12 months post-procedure
|
General Well-Being
Time Frame: 1,3,6,12 months post-procedure
|
General Well-Being is a term that may encompass mood, sense of well-being, family relationships, ability to do daily tasks and other practical or emotional practices that vary from person to person.
Patients will self-report changes in their Quality of Life
|
1,3,6,12 months post-procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Steven Silberfarb, DO, Florida Orthopaedics and Spine Center
- Study Chair: Steven Levy, MD, MD Stem Cells
- Principal Investigator: Jeffrey Weiss, MD, Coral Springs
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Trauma, Nervous System
- Paresis
- Spinal Cord Vascular Diseases
- Ischemia
- Wounds and Injuries
- Spinal Cord Diseases
- Paralysis
- Spinal Cord Injuries
- Paraparesis
- Paraplegia
- Spinal Cord Compression
- Spinal Cord Ischemia
Other Study ID Numbers
- SciExVR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Diseases
-
The University of Texas Health Science Center,...TerminatedSpinal Cord Injuries | Cervical Spinal Cord Injury | Traumatic Spinal Cord CompressionUnited States
-
Jill M. Wecht, Ed.D.Icahn School of Medicine at Mount SinaiRecruitingBlood Pressure | Spinal Cord Injuries | SCI - Spinal Cord Injury | Blood Pressure Disorders | Traumatic Spinal Cord Injury | Acute Spinal Cord Injury | Neuromodulation | Spinal Cord StimulationUnited States
-
Taipei Veterans General Hospital, TaiwanThe Industrial Technology Research InstituteUnknownSpinal Cord Injuries | Complete Spinal Cord Injury | Incomplete Spinal Cord InjuryTaiwan
-
University of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruitingSCI - Spinal Cord Injury | Incomplete Spinal Cord InjuryUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingMetastatic Epidural Spinal Cord CompressionUnited States
-
University of MiamiViewray Inc.Not yet recruitingSpinal Cord Compression | Metastatic Epidural Spinal Cord CompressionUnited States
-
NervGen PharmaRecruitingSpinal Cord Injuries | Chronic Spinal Cord Injury | Subacute Spinal Cord InjuryUnited States
-
M.D. Anderson Cancer CenterBrainlab AGNot yet recruitingSpinal Cord | Metastatic Epidural | Spine StereotacticUnited States
-
Ankara City Hospital BilkentActive, not recruitingChronic Spinal Cord DisorderTurkey
-
MetroHealth Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS); Case Western...RecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Spinal Cord Injury CervicalUnited States
Clinical Trials on Paraspinal
-
Spine Centre of Southern DenmarkOdense University Hospital; Frederiksberg University Hospital; Center for Rheumatology...CompletedPain | Back Pain | Lumbar Disc Herniation | Spinal Diseases | SurgeryDenmark
-
Washington University School of MedicineTerminatedMetastasesUnited States
-
Peking University Third HospitalRecruitingDegenerative Scoliosis | Degenerative Lumbar Spinal StenosisChina
-
Mercy ResearchCompletedArteriovenous Malformations | Neurofibroma | Chordoma | Meningioma | Schwannoma | Spinal Metastases | Paragangliomas | Vertebral Metastases | Benign Spinal TumorsUnited States
-
Nemours Children's ClinicZimmer BiometCompletedPain, Postoperative | Pectus ExcavatumUnited States
-
Peking University Cancer Hospital & InstituteNot yet recruitingMetastatic Castration-resistant Prostate Cancer
-
Hacettepe UniversityRecruitingMultiple Sclerosis | AtaxiaTurkey
-
Hospital de Clinicas de Porto AlegreAssociação Fundo de Incentivo à PesquisaCompletedChronic Pain | Knee OsteoarthritisBrazil
-
University of FloridaCompleted
-
China-Japan Friendship HospitalRecruitingUniportal Video-assisted Thoracic SurgeryChina